SCHEMBL6316239

SCHEMBL6316239

Cc1ccccc1CNC(=O)c1c(-c2coc3ccccc23)noc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ADORA2A P29274 3/20 0.43
ADORA1 P30542 3/20 0.43
NPC1 O15118 1/20 0.42
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2B P29275 1/20 0.41
KMT2A Q03164 2/20 0.40
P2RX7 Q99572 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
ALOX15 P16050 1/20 0.39
APEX1 P27695 1/20 0.39
RECQL P46063 1/20 0.39
BCL2L1 Q07817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315709 0.88 CHRNB2 (0.43) ADORA2AADORA1NPC1MAPTSMN1; SMN2
SCHEMBL6319043 0.88 NPC1 (0.46) HPGDALDH1A1KDM4EADORA2AADORA1
SCHEMBL6317961 0.88 ALDH1A1 (0.45) ALDH1A1KDM4ENPC1MAPTTP53
SCHEMBL6315362 0.88 RXFP1 (0.46) HPGDALDH1A1ADORA2AADORA1NPC1
SCHEMBL6316721 0.87 NPC1 (0.55) HPGDALDH1A1KDM4EADORA2AADORA1
SCHEMBL6324110 0.86 MAPT (0.50) HPGDALDH1A1NPC1MAPTTP53
SCHEMBL6324322 0.85 NTRK1 (0.43) HPGDADORA2AADORA1NPC1KMT2A
SCHEMBL6316863 0.84 MAPT (0.48) HPGDALDH1A1KDM4EMAPTKMT2A
SCHEMBL6318963 0.84 ALDH1A1 (0.47) HPGDALDH1A1KDM4EADORA2AADORA1
SCHEMBL6316206 0.83 POLB (0.53) HPGDALDH1A1KDM4ENPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 HPGD 2923/4885ALDH1A1 4444/4885KDM4E 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.